CNO Financial Group(US:CNO)2023-02-08 20:17Financial Data and Key Metrics Changes - The company reported operating earnings per share of $2.33, reflecting ongoing market volatility and moderation in alternative investment returns [13] - The total margin was essentially flat, indicating stable underlying dynamics despite challenges [42] - Book value per diluted share, excluding AOCI, increased by 11%, nearing $30 per diluted share [27] Business Line Data and Key Metrics Changes - Annuity collected premiums were up 8% for the quarter and 15% year-over-year, marking the ninth consecutive quarter of growth [6] - Direct-to-consumer life sales increased by 9% for the quarter and 10% for the year, continuing a trend of double-digit growth [8] - Supplemental health sales rose by 26% for the quarter and 9% for the year, with Medicare Supplement sales up 30% sequentially [29][30] Market Data and Key Metrics Changes - Client assets in brokerage and advisory decreased by 9% year-over-year to $2.6 billion due to market volatility [20] - The company managed over $13 billion in assets for clients, combining annuity account values with brokerage and advisory assets [20] - The consolidated RBC ratio improved to 384%, up from 375% at the end of the previous quarter [48] Company Strategy and Development Direction - The company aims to capitalize on the capabilities of the Optavise brand to expand market reach in 2023 and beyond [2] - The integration of agent field force and direct-to-consumer distribution is expected to drive growth in the Consumer Division [28] - The company is focused on maintaining strong fundamentals and positioning for growth amid economic uncertainty [25][50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in growth and shareholder return opportunities, emphasizing the importance of guidance and products in uncertain economic times [50] - The transition from pandemic to endemic stages is expected to impact results, with a cautious outlook for the early part of the year due to potential recessionary pressures [56] - The company plans to provide more detailed outlooks at the upcoming Investor Day [40][52] Other Important Information - The company returned $245 million to shareholders in the year, including $180 million in share buybacks [27] - The Optavise brand has shown early signs of being a recruiting catalyst, with improved conversion rates for new agents [34] - The company is maintaining excess capital above target levels due to near-term economic risks [48] Q&A Session Summary Question: Impact of COVID on health underwriting margin - Management noted favorable case reserve development and indicated that results will reflect the transition to an endemic stage, with changes under LDTI expected to alter dynamics [55][56] Question: Share buyback cadence - Management suggested a cautious approach in the early part of the year, with expectations to settle into a run rate later in 2023 [57][58] Question: Dynamics in agent force and retention trends - Management explained that producing agent count lags new agent recruitment, but productivity has been trending positively [61][62] Question: Timing for sales to impact margins - Management indicated that new sales typically contribute to margin in subsequent years, with a lag in recognition [66][67] Question: Feedback on Medicare Supplement product - Management reported positive feedback from agents and indicated potential for minor tweaks rather than major changes [71][72]